Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
H2APEX Group SCA (H2A.DE)
Rostock, DE
H2APEX Group SCA focuses on the engineering, production, and management of facilities that generate green hydrogen. Its core mission is to support the de-carbonization of both industrial and infrastructural sectors within Germany and Luxembourg. The company's operations are divided into three distinct segments. The Operations segment is responsible for manufacturing and distributing green hydrogen, along with generating derived products like electricity and heat. The Project Development segment offers services encompassing project planning and system integration for external hydrogen plants, providing flexible, technology-independent, and bespoke turnkey hydrogen supply solutions. Lastly, the Storage segment is dedicated to creating and fabricating diverse hydrogen storage systems. H2APEX serves a broad range of clients, including transportation and logistics providers, industrial companies, engineering firms, research institutions, government entities, and automotive manufacturers. Founded in 2000, H2APEX Group SCA is based in Rostock, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.90% | +20.33% | +23.59% | -26.01% | -34.43% | -46.32% | -53.21% | -84.01% | -75.00% | -63.50% | -88.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+159.0% ★ Q1'26: +293.3% (vs Q2'23)
-
EPS growth Chemicals - Specialty: +13.2%-321.1% Q1'26: -23.1% (vs Q2'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-347.2% Q1'26: -161.2% (vs Q2'23)
-
EBIT margin Chemicals - Specialty: +8.8%-322.1% Q1'26: -221.2% (vs Q2'23)
-
ROIC Chemicals - Specialty: +5.6%-57.5% Q1'26: -58.3% (vs Q2'23)
-
Share dilution Chemicals - Specialty: +0.1%+111.3% Q1'26: +37.9% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×-1.26× Q1'26: -1.41× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
28.20M
est.
|
9.97M
est: 9.73M (+2.4%)
|
14.36M
13.07M – 15.30M
+47.5% YoY
|
26.89M
24.18M – 31.20M
+87.3% YoY
|
44.71M
40.37M – 50.40M
+66.2% YoY
|
122.30M
110.43M – 137.87M
+173.6% YoY
|
| EBITDA |
-7.85M
est.
|
-28.90M
est: -2.71M (-966.6%)
|
-4.00M
-4.26M – -3.64M
-47.5% YoY
|
-7.49M
-8.69M – -6.73M
-87.3% YoY
|
-12.45M
-14.03M – -11.24M
-66.2% YoY
|
-34.05M
-38.38M – -30.74M
-173.6% YoY
|
| EBIT |
-10.22M
est.
|
-32.09M
est: -3.53M (-809.6%)
|
-5.20M
-5.55M – -4.74M
-47.5% YoY
|
-9.75M
-11.31M – -8.77M
-87.3% YoY
|
-16.21M
-18.27M – -14.63M
-66.2% YoY
|
-44.33M
-49.98M – -40.03M
-173.6% YoY
|
| Net Income |
-14.33M
est.
|
-33.76M
est: -14.84M (-127.5%)
|
-10.49M
-12.94M – -8.03M
+29.3% YoY
|
-5.14M
-6.02M – -4.26M
+50.9% YoY
|
-3.11M
-3.56M – -2.67M
+39.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
10.20M
est.
|
7.37M
est: 3.52M (+109.5%)
|
5.19M
4.72M – 5.53M
+47.5% YoY
|
9.72M
8.74M – 11.28M
+87.3% YoY
|
16.17M
14.60M – 18.22M
+66.2% YoY
|
44.22M
39.93M – 49.85M
+173.6% YoY
|
| EPS |
-0.71
est.
|
-0.80
est: -0.70 (-14.3%)
|
-0.48
-0.64 – -0.40
+31.2% YoY
|
-0.26
-0.30 – -0.21
+46.5% YoY
|
-0.15
-0.18 – -0.13
+40.9% YoY
|
—
— – —
+100.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bert Althaus | MD & CFO | — | male |
| Jan Klopp | MD & Member of Management Board of H2APEX Management S.à r.l | — | male |
| Klaus Rohrig | MD, Supervisory Board Member & Member of Management Board of H2APEX Management S.à r.l. | — | male |
| Ludger Schlüter | Chief Operating Officer | — | male |
| Peter Roßner | Chief Executive Officer | — | male |
| Philipp Klecka | MD & Member of Management Board of H2APEX Management S.à r.l | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for H2A.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
